

## Press Release

---

# Nicox Announces Research Collaboration on Novel Ophthalmic Therapeutics with Ironwood Pharmaceuticals

---

June 6, 2018 – release at 7:30 am CET  
Sophia Antipolis, France

**Nicox SA** (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced its entry into a research collaboration with Ironwood Pharmaceuticals, Inc. (“Ironwood”), a commercial biotechnology company, focused on combining Ironwood’s expertise in soluble guanylate cyclase (sGC) and Nicox’s proprietary nitric oxide (NO)-donating research platform to generate novel compounds in order to identify potential new therapeutics for the treatment of certain ophthalmic conditions.

Under the terms of the research collaboration agreement, each company will be responsible for their own costs associated with activities carried out as part of the collaboration. Depending on the outcome of the research collaboration, Nicox and Ironwood may then enter into discussions regarding Nicox’s further development of any identified product candidate.

**Michael Bergamini, Ph.D., Executive Vice President, Chief Scientific Officer of Nicox, commented,** *“There is evidence to suggest that bringing together Ironwood and Nicox’s respective expertise in sGC and NO-donating compounds can create new treatment options for ophthalmic conditions. We look forward to working with Ironwood on this exciting collaboration, with the goal of identifying potential new Nicox development pipeline candidates.”*

---

### About Nicox

Nicox S.A. is an international ophthalmic company, with two out-licensed commercial-stage products, developing innovative solutions to help maintain vision and improve ocular health. By leveraging its proprietary expertise in nitric oxide donation and other technologies, the Company is developing an extensive portfolio of novel drug candidates that target multiple ophthalmic conditions, including glaucoma. Nicox currently has two products with approved New Drug Applications, VYZULTA™ (latanoprostene bunod ophthalmic solution) 0.024%, licensed worldwide to Bausch + Lomb, and ZERVIA™ (cetirizine ophthalmic solution) 0.24%, licensed in the U.S. to Eyeavance. In addition, our promising drug-candidate pipeline includes clinical stage assets based both on our proprietary NO-donating research platform and on the repurposing of existing molecules as well as a next-generation of stand-alone nitric-oxide donors and exploratory novel NO-donating compounds with the potential to offer novel approaches to treat a range of ophthalmic conditions. Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes.

For more information on Nicox, its products or pipeline, please visit: [www.nicox.com](http://www.nicox.com).

## Analyst coverage

---

Bryan, Garnier & Co	Hugo Solvet	Paris, France
Invest Securities	Martial Descoutures	Paris, France
Gilbert Dupont	Damien Choplain	Paris, France



*The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.*

## Upcoming financial and business conferences

---

June 4-7	2018 BIO International Convention	Boston, USA
June 27-28	European MidCap Event	Paris, France
October 1-3	Cantor Global Annual Healthcare Conference	New York, USA
November 22-23	Bryan Garnier 6 <sup>th</sup> Annual Healthcare Conference	Paris, France

## Contacts

---

### Nicox

Gavin Spencer,  
Executive Vice President Corporate Development  
T +33 (0)4 97 24 53 00  
[communications@nicox.com](mailto:communications@nicox.com)

### Investor Relations

Europe  
Nicox  
Corporate Communications Department  
T +33 (0)4 97 24 53 00  
[communications@nicox.com](mailto:communications@nicox.com)

### United States

Argot Partners  
Melissa Forst  
T +1 (212) 600-1902  
[melissa@argotpartners.com](mailto:melissa@argotpartners.com)

### Media Relations

United Kingdom  
Jonathan Birt  
T +44 7860 361 746  
[jonathan.birt@ymail.com](mailto:jonathan.birt@ymail.com)

### France

NewCap  
Nicolas Merigeau  
T +33 (0)1 44 71 94 98  
[nicox@newcap.eu](mailto:nicox@newcap.eu)

### United States

Argot Partners  
David Rosen  
T +1 (212) 600-1902  
[david.rosen@argotpartners.com](mailto:david.rosen@argotpartners.com)

### Italy

Argon Healthcare International  
Pietro Pierangeli  
[pietro.pierangeli@argonhealthcare.com](mailto:pietro.pierangeli@argonhealthcare.com)  
Chiara Tettamanti  
[chiara.tettamanti@argonhealthcare.com](mailto:chiara.tettamanti@argonhealthcare.com)  
T. +39 02 4951.8300

## Disclaimer

---

The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.

Risks factors which are likely to have a material effect on Nicox's business are presented in the 4th chapter of the '*Document de référence, rapport financier annuel et rapport de gestion 2016*' filed with the French Autorité des Marchés Financiers (AMF) on March 29, 2017, and in the updated and additional risk factors as of August 14, 2017, which are available on Nicox's website ([www.nicox.com](http://www.nicox.com)).

**Nicox S.A.**

Drakkar 2  
Bât D, 2405 route des Dolines  
CS 10313, Sophia Antipolis  
06560 Valbonne, France  
T +33 (0)4 97 24 53 00  
F +33 (0)4 97 24 53 99